Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Bagsværd, Denmark, 12 June 2025 - Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies.

(RTTNews) - Novo Nordisk (NVO) announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. This decision was ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.